This Pot Stock Has Uplisted and Is Poised for Massive Profit Potential

As I've mentioned numerous times by now, Canada is right at the doorstep of becoming the first G7 nation where the use of recreational cannabis is legalized for the entire country.

I can't emphasize enough how big this is.

In fact, the recreational marijuana market in Canada could be valued at anywhere between $5 billion and $10 billion per year.

The company that I'll be talking about today is one that I first recommended to my Nova-X Report readers way back in 2016.

The company has recently gone through some exciting developments and can take advantage of the massive potential of the marijuana market.

You see, on May 24, the company uplisted, and its shares are currently trading on the New York Stock Exchange, in addition to trading on the Toronto Stock Exchange.

Here's why this move will maximize this stock's profit potential.

You see, uplisting will benefit the stock's price, liquidity, and potential appreciation.

First, by moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base.

Second, the exchanges and market participants are more likely to offer greater liquidity and price discovery and be more active in supporting and trading the stock.

So let's take a look at this Canadian pot stock and its potential for massive gains...

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Canada's Biggest Grower... Keeps On Growing

Canopy Growth Corp. (NYSE: CGC) is the biggest cannabis grower in Canada and has been expanding its capacity.

In fact, it's poised to be one of the major global players in the industry as marijuana legalization spreads to more countries.

In addition to exposure in the blossoming Canadian market, Canopy already has agreements to export products to Germany, Australia, Spain, Denmark, Jamaica, Chile, and Brazil.

RELATED: Top five tiny Canadian pot stocks are set to skyrocket. Click here...

What's more, one of Canopy's investors is alcoholic giant Constellation Brands Inc. (NYSE: STZ), with a 9.9% stake in the company. That stake is worth a cool $191 million, and Constellation will have the option of purchasing additional stakes in the future.

It's no coincidence that Constellation, which has a strong presence in California, made its move just months ahead of the state's full legalization of marijuana.

Over the past year, Canopy has put more emphasis on its cannabis-oils products, as well, citing the higher profit margins of oils in its September quarter earnings report. Sales from oils increased 107% year over year, and the segment's contribution to overall revenue rose from 14% to 18%.

The Brightfield Group estimates the global marijuana market will reach $31.4 billion by 2021. Should Canopy get 5% of the global cannabis market, it will grow sales by 250%.

Now, let's take a look at what the stock currently looks like.

Two Exchanges, Plenty of Gains

Canopy is looking strong by closing above its initial New York Stock Exchange listing high once more. Though the cannabis sector isn't yet fully on the same page, it can be comforted by the fact that Canopy, as its undisputed sector leader, continues to attract investors.

Shares of Canopy's WEED on the Toronto Stock Exchange gapped up to $40 per share before retreating 15.76% over the next two-plus sessions as profit takers gained control.

Today is the second time Canopy Growth has breached $40 per share on a closing basis. On June 6, which was the day before Canada's historic Bill C-45 vote was scheduled to take place, WEED finished at $40.68 per share after investors ran up prices in the sector in anticipation of a successful third reading vote.

Having accomplished that, the sector sold off around 8% over the next four days as a main underlying catalyst had been vanquished from the market.

Now that Canopy Growth has round tripped from sub-$34 and back - closing up $1.26 to $40.65 per share - investors have gotten past most of their recent post-legalization sell-off fears.

In fact, WEED closed just $0.03 shy of establishing a new post-NYSE closing high, meaning it can essentially set its sights on $41.40 and $44, which are the post-NYSE intraday high and all-time high, respectively.

Canopy's seemingly uncontrollable appetite shouldn't surprise anyone who is following the company. Last week, the company raised $500 million Canadian via convertible note offering, which was the largest ever in the cannabis space. The offering was upsized 25% from the previously $400 million Canadian aggregate principal amount announced just two days prior.

Endless Profit Opportunity for Just About Anyone

If you want to make a profit on the booming cannabis sector, then I suggest jumping onboard Canopy, where the opportunities and gains are seemingly endless.

But that's just scratching the surface.

For instance, my paid-up Nova-X Report subscribers get total access to my Roadmap to Marijuana Millions model portfolio and stock research, which includes a full briefing on no less than five small caps, each trading for around $5, that are poised to explode when, as expected, Canada passes legalization. This is the kind of potential than can turn a tiny stake into $100,000 or more.

When Canada Takes Weed Fully Legal...

It'll probably make our retrograde attorney general hopping mad, but there's really nothing on Earth he can do to stop these small cannabis companies from hitting the stratosphere. Sessions could be furious, but folks who park a few hundred dollars into these "north of the border" firms could potentially turn a small stake into $100,000 - and fast. Michael Robinson has the details for you - click here to hear what he's got to say...

Follow Money MorningonFacebook, Twitter, and LinkedIn.

About the Author

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...

  • He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
  • He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
  • As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael's insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.

Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

Read full bio